 |
|
Human Immunodeficiency Virus 1 Protease Inhibitors in Clinical Practice
Predictors of Virological Outcome
Hernan Valdez, MD;
Michael M. Lederman, MD;
Ian Woolley, MD;
Courtney J. Walker, BA;
Lance T. Vernon, BA;
Amy Hise, MD;
Barbara M. Gripshover, MD
Arch Intern Med. 1999;159:1771-1776.
Objectives To ascertain whether prolonged suppression of viral replication can be achieved in clinical practice and to identify factors associated with virological outcome.
Design Retrospective observational study.
Setting University-affiliated human immunodeficiency virus (HIV) clinic in Cleveland, Ohio.
Participants Patients treated with regimens that included protease inhibitors between June 1995 and December 1997. We identified 366 patients; 310 had sufficient virological follow-up data to be included.
Main Outcome Measure Virological success was defined as plasma HIV-RNA levels lower than 400 copies/mL at the last clinic visit. Virological failure was subdivided according to the maximum degree of suppression of viral replication achieved. Multivariate analysis was performed to identify baseline factors associated with virological outcome.
Results Virological success was achieved by 47% of patients at a median follow-up of 335 days. The median CD4+ cell count increase and HIV-RNA level decrease were 0.10x109/L (100 cells/µL) and greater than 1.3 log10 in patients who achieved virological success, and 0.010x109/L and 0.32 log10 for those who did not. In multivariate analysis the likelihood of virological success was diminished in women (P<.02) and in patients who missed 2 or more clinic visits in the prior year (P<.001), and decreased when the regimen was started earlier (P<.04). Patients with a lower nadir CD4+ cell count (P<.04) and higher peak plasma HIV-RNA levels (P<.001) also had a decreased likelihood of virological success.
Conclusions More than half the patients who started a regimen that included protease inhibitors in an academic clinical practice failed to achieve durable suppression of viral replication and also experienced a poorer immunologic outcome as determined by CD4+ cell count increase. Missed clinic visits, more advanced disease, and higher plasma HIV-RNA levels may predict failure.
From the Center for AIDS Research, Case Western Reserve University (Drs Valdez, Lederman, and Gripshover and Ms Walker), and the University Hospitals of Cleveland (Drs Valdez, Lederman, Woolley, Hise, and Gripshover), Cleveland; and the Brecksville Veterans Affairs Medical Center, Brecksville (Mr Vernon), Ohio.
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 1999;159(15):1818-1819.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age
Sanders et al.
ANN INTERN MED 2008;148:889-903.
ABSTRACT
| FULL TEXT
The Cost-Effectiveness of Counseling Strategies to Improve Adherence to Highly Active Antiretroviral Therapy among Men Who Have Sex with Men
Zaric et al.
Med Decis Making 2008;28:359-376.
ABSTRACT
The Physical, Emotional and Interpersonal Impact of HAART: Exploring the Realities of HIV Seropositive Individuals on Combination Therapy
Halkitis et al.
J Health Psychol 2005;10:345-358.
ABSTRACT
Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy
Sanders et al.
NEJM 2005;352:570-585.
ABSTRACT
| FULL TEXT
R57K Polymorphism in the Human Immunodeficiency Virus Type 1 Protease as Predictor of Early Virological Failure in a Cohort of Antiretroviral-Naive Patients Treated Mostly with a Nelfinavir-Containing Regimen
Masquelier et al.
Antimicrob. Agents Chemother. 2003;47:3623-3626.
ABSTRACT
| FULL TEXT
Effect of Case Management on Unmet Needs and Utilization of Medical Care and Medications among HIV-Infected Persons
Katz et al.
ANN INTERN MED 2001;135:557-565.
ABSTRACT
| FULL TEXT
A Randomized, Double-Blind Study of Triple Nucleoside Therapy of Abacavir, Lamivudine, and Zidovudine Versus Lamivudine and Zidovudine in Previously Treated Human Immunodeficiency Virus Type 1-Infected Children
Sáez-Llorens et al.
Pediatrics 2001;107:4e-4.
ABSTRACT
| FULL TEXT
Immune Restoration With Antiretroviral Therapies: Implications for Clinical Management
Lederman and Valdez
JAMA 2000;284:223-228.
ABSTRACT
| FULL TEXT
|
